Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 7/20 | 0.42 |
| ▸ | ALKBH1 | Q13686 | 3/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12876120 | 0.91 | MMP13 (0.46) | KMT2ADHODHMMP13GRM5KLKB1 | |
| SCHEMBL1198589 | 0.88 | MMP13 (0.40) | KMT2AMMP13MMP2MMP1MMP9 | |
| SCHEMBL12876201 | 0.87 | KLKB1 (0.40) | KMT2ADHODHKLKB1 | |
| Trifluoroacetic Acid SCHEMBL2863073 | 0.86 | GPR132 (0.39) | KMT2AMMP13MMP2MMP1MMP9 | |
| SCHEMBL12875995 | 0.86 | ALKBH1 (0.48) | KMT2AALKBH1KLKB1PPARDPPARA | |
| SCHEMBL12876017 | 0.83 | MEN1 (0.41) | KMT2AALKBH1KLKB1PPARDPPARA | |
| SCHEMBL1198663 | 0.82 | MMP13 (0.44) | KMT2AMMP13PPARDPPARA | |
| SCHEMBL12876136 | 0.82 | ALKBH1 (0.50) | ALKBH1KDM4CKLKB1PPARDPPARA | |
| SCHEMBL1198990 | 0.81 | EGLN1 (0.52) | ALKBH1PPARDPPARA | |
| SCHEMBL12876187 | 0.81 | GRM5 (0.38) | KMT2AGRM5KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | KMT2A 3197/4885DHODH 462/4885MMP13 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.